Maria Themeli
Overview
Explore the profile of Maria Themeli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1567
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Katsarou A, Sjostrand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, et al.
Sci Transl Med
. 2021 Dec;
13(623):eabh1962.
PMID: 34878825
Despite the high remission rates achieved using T cells bearing a chimeric antigen receptor (CAR) against hematogical malignancies, there is still a considerable proportion of patients who eventually experience tumor...
12.
van de Donk N, Themeli M, Usmani S
Blood Cancer Discov
. 2021 Aug;
2(4):302-318.
PMID: 34386775
BCMA-specific CAR T-cells have substantial therapeutic potential in multiple myeloma (MM), but most patients eventually relapse. Determinants of response and mechanisms of resistance are most likely multifactorial and include MM-related...
13.
Stikvoort A, van der Schans J, Sarkar S, Poels R, Ruiter R, Naik J, et al.
Hemasphere
. 2021 Jun;
5(7):e596.
PMID: 34131635
Chimeric antigen receptor (CAR) T cells are highly successful in the treatment of hematologic malignancies. We recently generated affinity-optimized CD38CAR T cells, which effectively eliminate multiple myeloma (MM) cells with...
14.
Holthof L, van der Schans J, Katsarou A, Poels R, Gelderloos A, Drent E, et al.
Clin Cancer Res
. 2021 Apr;
27(13):3793-3803.
PMID: 33883175
Purpose: The microenvironment of multiple myeloma (MM) can critically impair therapy outcome, including immunotherapies. In this context, we have earlier demonstrated that bone marrow mesenchymal stromal cells (BMMSC) protect MM...
15.
Melsen J, Themeli M, van Ostaijen-Ten Dam M, van Beelen E, Lugthart G, Hoeben R, et al.
Bio Protoc
. 2021 Mar;
10(23):e3845.
PMID: 33659493
Natural killer (NK) cells are innate immune cells, characterized by their cytotoxic capacity, and chemokine and cytokine secretion upon activation. Human NK cells are identified by CD56 expression. Circulating NK...
16.
Poels R, Drent E, Lameris R, Katsarou A, Themeli M, van der Vliet H, et al.
Int J Mol Sci
. 2021 Jan;
22(3).
PMID: 33499253
Due to the CD1d restricted recognition of altered glycolipids, Vα24-invariant natural killer T (iNKT) cells are excellent tools for cancer immunotherapy with a significantly reduced risk for graft-versus-host disease when...
17.
Flippe L, Gaignerie A, Serazin C, Baron O, Saulquin X, Themeli M, et al.
Front Cell Dev Biol
. 2020 Nov;
8:577464.
PMID: 33195214
Cell therapy using T cells has revolutionized medical care in recent years but limitations are associated with the difficulty of genome editing of the cells, the production of a sufficient...
18.
Themeli M, Chhatta A, Boersma H, Prins H, Cordes M, de Wilt E, et al.
Stem Cell Reports
. 2020 Jan;
14(2):300-311.
PMID: 31956083
RAG2 severe combined immune deficiency (RAG2-SCID) is a lethal disorder caused by the absence of functional T and B cells due to a differentiation block. Here, we generated induced pluripotent...
19.
Akbari P, Huijbers E, Themeli M, Griffioen A, van Beijnum J
Angiogenesis
. 2019 Oct;
22(4):473-475.
PMID: 31628559
T cells armed with a chimeric antigen receptor, CAR T cells, have shown extraordinary activity against certain B lymphocyte malignancies, when targeted towards the CD19 B cell surface marker. These...
20.
Depreter B, Weening K, Vandepoele K, Essand M, De Moerloose B, Themeli M, et al.
Haematologica
. 2019 Aug;
105(5):1306-1316.
PMID: 31371409
Immunotherapeutic strategies targeting the rare leukemic stem cell compartment might provide salvage to the high relapse rates currently observed in acute myeloid leukemia (AML). We applied gene expression profiling for...